Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dabigatran + ticagrelor + acetylsalicylic acid
- Development stage
- Phase 4
- Lead developer
- Boehringer Ingelheim
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy consisting of dabigatran (an oral direct thrombin inhibitor), ticagrelor (a P2Y12 receptor antagonist), and acetylsalicylic acid (aspirin). This triple antithrombotic regimen may be used in patients with atrial fibrillation who undergo percutaneous coronary intervention or have acute coronary syndrome. Clinical evidence suggests this combination significantly increases bleeding risk compared to dual therapy alternatives.
- Other names
- triple antithrombotic therapy
02
Targets
PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)P2Y12 (Purinergic P2Y12 receptor)F2 (Thrombin)
Beyond the preview
Go deeper on dabigatran + ticagrelor + acetylsalicylic acid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dabigatran + ticagrelor + acetylsalicylic acid.